Neos Therapeutics Inc. (NASDAQ:NEOS) was down 3.4% on Wednesday . The stock traded as low as $6.99 and last traded at $7.08, with a volume of 102,779 shares. The stock had previously closed at $7.33.

Several equities research analysts recently weighed in on NEOS shares. Royal Bank Of Canada decreased their price target on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. Zacks Investment Research downgraded Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. Finally, BMO Capital Markets assumed coverage on Neos Therapeutics in a report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price target for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $21.75.

The firm’s market capitalization is $109.44 million. The stock has a 50-day moving average of $8.34 and a 200-day moving average of $9.43.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.49. The business earned $1.49 million during the quarter, compared to the consensus estimate of $1.48 million. On average, equities analysts expect that Neos Therapeutics Inc. will post ($5.38) EPS for the current fiscal year.

In other news, CFO Richard I. Eisenstadt purchased 3,710 shares of the stock in a transaction dated Thursday, August 25th. The stock was acquired at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the acquisition, the chief financial officer now owns 3,710 shares of the company’s stock, valued at $25,302.20. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Juergen Martens purchased 10,000 shares of the stock in a transaction dated Monday, June 13th. The stock was purchased at an average price of $9.90 per share, with a total value of $99,000.00. Following the completion of the acquisition, the insider now directly owns 10,000 shares in the company, valued at approximately $99,000. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Neos Therapeutics stock. Marshall Wace LLP boosted its position in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned about 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent filing with the SEC.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.